AVITA Medical, Inc. (RCEL)
11.20
+0.26
(+2.38%)
USD |
NASDAQ |
Sep 04, 16:00
11.16
-0.04
(-0.36%)
After-Hours: 20:00
AVITA Medical Research and Development Expense (Quarterly) : 5.078M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.078M |
| March 31, 2026 | 5.629M |
| December 31, 2025 | 5.691M |
| September 30, 2025 | 3.748M |
| June 30, 2025 | 5.117M |
| March 31, 2025 | 6.284M |
| December 31, 2024 | 4.85M |
| September 30, 2024 | 5.428M |
| June 30, 2024 | 4.887M |
| March 31, 2024 | 5.194M |
| December 31, 2023 | 6.765M |
| September 30, 2023 | 4.394M |
| Date | Value |
|---|---|
| June 30, 2023 | 5.076M |
| March 31, 2023 | 4.586M |
| December 31, 2022 | 3.379M |
| September 30, 2022 | 3.799M |
| June 30, 2022 | 3.059M |
| March 31, 2022 | 3.62M |
| June 30, 2021 | 3.974M |
| March 31, 2021 | 4.109M |
| December 31, 2020 | 3.361M |
| September 30, 2020 | 3.204M |
| June 30, 2020 | 2.332M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 27.66M |
| Iovance Biotherapeutics, Inc. | 58.85M |
| Amgen, Inc. | 1.868B |
| Editas Medicine, Inc. | 19.76M |
| Arcus Biosciences, Inc. | 113.00M |